Introduction {#s1}
============

In the human species, females have longer life expectancies than males. The most recent US census data (<http://www.census.gov>) reports that males have a life expectancy of 75.5 years and females 80.5 years. Throughout this manuscript, we will define this phenomenon as the "gender effect". This gender effect was masked in the past due to high rates of maternal death from childbirth [@pone.0061955-Austad1]. The effect is now clearly visible throughout the developed world, with the only exceptions being underdeveloped countries where health systems are not capable to limit maternal deaths and the life expectancy is still that observed in developed countries one century ago [@pone.0061955-Austad1].

Over the last two decades, the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute has collected information on cancer incidence, prevalence and survival in the United States. The SEER database is freely accessible and comprises geographic areas representing 28 percent of the US population. In our opinion, this database represents a useful source to address the gender effect in cancer. An analysis using the SEER database by Cook et al. in 2009 focused on gender differences in the incidence of cancer [@pone.0061955-Cook1]. This study clearly demonstrated that the risk of malignancy is higher in males, relative to females, for a majority of cancers at most ages. A second study by Cook et al addressed cancer mortality rate and noted a trend toward worse survival in men for a number of cancers. The authors noted that this trend tended to reflect the previously described pattern in cancer incidence [@pone.0061955-Cook2]. One limitation of these studies is that the authors considered the gender effect as constant throughout lifetime. Indeed, at birth the differences by gender are minimal. At puberty, however, with the acquisition of sexual maturity, gender differences start to appear and ultimately peak during young adulthood. These differences begin to decrease in middle to advanced adulthood, with the decrease in gonadic sex hormone production.

The National Health and Nutrition Examination Survey (NHANES) is a survey research program conducted by the National Center for Health Statistics to assess the health and nutritional status of US population. The survey combines interviews and physical examinations, including medical, dental, and physiological measurements, as well as laboratory tests administered by medical personnel, thus providing a snapshot of the health status of the US population.

We sought to address this gap in the field by determining the relevance of the gender effect on survival analysis with respect to age as a continuous variable and possible relation to physiological variables assessed in the NHANES III population study.

Materials and Methods {#s2}
=====================

SEER database {#s2a}
-------------

The April 2012 release of the 1973--2009 SEER-18 Research Data in SEER\*Stat version 7.0.9 was used for this study. Information from 3,133,120 patients was initially collected and used to analyze five year cause-specific survival for all cancer sites defined in the database. Case selection was defined as actively followed cases in the research database with malignant behavior and age at diagnosis of 1 to 84 years of age. Cases with death certificate only or autopsy only, cases based on multiple primaries and cases alive with no survival time were excluded (n = 189,718). Only patients for whom information was available about race, tumor stage, tumor type, gender and age at diagnosis were included. Analysis excluded gender specific sites (ovary, endometrial, vaginal, testis and prostate cancer). Breast cancer was not included because of the disproportionate frequency by gender. Details of the ICD codes of the excluded diseases are provided in [Table 1](#pone-0061955-t001){ref-type="table"}. This limited the sample size to 1,194,490 patients. The SEER cause-specific death classification was set as the definition of cause of death. The primary endpoint was cause-specific survival of each patient\'s originally diagnosed cancer site. Cause-specific survival was censored at the last follow-up, December 31, 2009, or five years after diagnosis, whichever came first. To analyze for gender-based survival differences, cases were stratified by males and females. Cases were further stratified by histological type and SEER Historic Stage (LRD Stage) [@pone.0061955-Henson1].
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###### Break down of genitalia tumors excluded from the analysis.

![](pone.0061955.t001){#pone-0061955-t001-1}

  Tissue                              ICD-9 codes     Number of male patients   Number of female patients  
  --------------------------------- ---------------- ------------------------- --------------------------- -----------
  **Breast**                          175 (males);             4,641                     689,952           
                                     174 (females);                                                        
  **Cervix Uteri**                        180;                                           60,076            
  **Corpus Uteri**                        182;                                           144,621           
  **Other Female Genital Organs**      184; 181;                                          4,090            
  **Other Male Genital Organs**           187;                 1,150                                       
  **Ovary**                               183;                                           79,546            
  **Penis**                               187;                 3,514                                       
  **Prostate**                            185;                711,145                                      
  **Testis**                              186;                34,250                                       
  **Uterus, NOS**                         179;                                            2,451            
  **Vagina**                              184;                                            3,006            
  **Vulva**                               184;                                           10,470            
  **Total**                                                   754,700                    994,212            1,748,912

NHANES III dataset {#s2b}
------------------

NHANES III is the seventh in a series of surveys that began in 1960 to examine the health of the US population. NHANES III sampled approximately 40,000 individuals from 1988 through 1994. One-hundred thirty variables related to human health were included in the analysis. All the variables were computed as provided in the dataset. The variables taken into consideration are included in the lab file available at <http://www.cdc.gov/nchs/nhanes/nh3data.htm>. Such variables are reported with two different scales, one in the native scale and the other one after conversion in the international system of units, thus representing 65 independent variables in two different measurement units. In particular free testosterone index was calculated according to the formula FTI (Free Testosterone Index)  =  \[(TT/SHBG) \* 100\], as suggested by the document file attached to the dataset <ftp://ftp.cdc.gov/pub/health_statistics/nchs/nhanes/nhanes3/25a/sshormon.pdf>.

Statistical analysis {#s2c}
--------------------

Cox proportional hazards models were used to estimate the male to female hazard of cause-specific mortality, defined here as the cause of death being the specific cancer originally diagnosed and death being within five years of cancer diagnosis. A Hazard Ratio (HR) value of 1 means no difference compared to the reference, while a value lower or higher than 1 means decreased or increased risk, respectively. Multivariate analysis model included the following variables: age at diagnosis, tumor stage, cancer type (sarcoma, solid tumor or hematologic malignancy), race and gender.

Overall Survival (OS) was calculated from the date of diagnosis to the date of death or five years after diagnosis. Medians and life tables were computed using the product-limit estimate by the Kaplan-Meier method, and the Log-Rank test was employed to assess statistical significance. Analysis was performed using the same variables described above.

To assess the homology between the distribution of the HR across age and gender, the distribution of each parameter analyzed in the NHANES III dataset was computed across the available age range and the Spearman correlation test was computed to detect the presence of a statistically significant correlation. To further assess the homology between the variables an additional analysis was conducted. Two samples kolmogorov-smirnov (KS) test assessed the homology between the HR distribution and the distribution of a given variable in the NHANES III dataset. The null distribution of this statistic was calculated under the null hypothesis that the samples were drawn from the same distribution. Since the HR and the NHANES III variables have different scales, the z-score was computed for each variable according to the following equation:, where µ and σ are mean and standard deviation of the whole population, respectively. Due to the differences of size of the two databases used for this study (SEER n = 1,194,490; NHANES III n = 29,314) we used the technique of bootstrapping (n = 10,000) to sample from the SEER database an equal number of patients capable to match for each age the size of the NHNAES III database, using the R function censboot [@pone.0061955-Efron1]. For each bootstrap, a KS test was made and the results are expressed as % of homology, which was the % of KS tests demonstrating that the two samples were coming from the same distribution. In all cases the level of significance was set at a p value \<0.05.

Results {#s3}
=======

A multivariate Cox proportional hazard model was generated with gender, race, stage, tumor type as categorical variables and age as a continuous variable. The outcome variable was five year survival. After excluding for gender-specific cancers ([Table 1](#pone-0061955-t001){ref-type="table"}), approximately 1,200,000 cases from the SEER-18 database were analyzed. All the variables included in the model were highly significant at a p\<0.00001 ([Table 2](#pone-0061955-t002){ref-type="table"}). Caucasians (HR 0.75 CI 0.74--0.76) had a better survival than African-Americans, while epithelial solid tumors (HR 1.8 CI 1.79--1.83) and sarcomas (HR 1.61 CI 1.57--1.66) showed a worse outcome than hematologic malignancies (reference = 1). Stage of cancer significantly affected the outcome, with patients featuring a tumor with regional (HR 0.84 CI 0.83--0.84) or local (HR 0.21 CI 0.21--0.21) involvement having a higher chance of survival as compared to patients with distant metastatic disease. Age (HR 1.03 CI 1.03--1.03) and gender (HR 1.13 CI 1.12--1.13) had a marginal but significant effect, with males exhibiting a more aggressive disease and a lower chance (∼13%) of surviving five years post-diagnosis.
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###### Multivariate Cox analysis from the SEER 18 database.
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                      Number of patients   Number of deaths   HR[\*](#nt101){ref-type="table-fn"}   95% CI\*\*   P-Value
  ------------------ -------------------- ------------------ ------------------------------------- ------------ ---------
  **Gender**                                                                                                     \<2e-16
  Female                   517,765             185,363                   1 (Reference)                          
  Male                     676,725             255,117                       1.12                   1.12--1.13  
  **Age**                                                                    1.03                   1.03--1.03   \<2e-16
  **Race**                                                                                                       \<2e-16
  African-American         127,531              58,533                   1 (Reference)                          
  Caucasian               1,066,959            381,947                       0.75                   0.74--0.76  
  **Tumor**                                                                                                      \<2e-16
  Hematological             98,642              35,650                   1 (Reference)                          
  Sarcoma                   21,431              5,556                        1.61                   1.57--1.66  
  Solid                   1,074,417            399,274                       1.81                   1.79--1.83  
  **Stage**                                                                                                      \<2e-16
  Distant                  417,434             224,375                   1 (Reference)                          
  Localized                525,007              84,903                       0.21                   0.21--0.21  
  Regional                 252,049             131,202                       0.84                   0.83--0.84  

HR = Hazard Ratio \*\*CI = Confidence Interval.

Thereafter, we adopted the same Cox proportional hazard model and calculated the HR over the entire age range (0 to 84 years). As depicted in [Fig. 1](#pone-0061955-g001){ref-type="fig"}, we used females as reference (HR = 1). No significant effects were noticed in the age range 0--17 years. From 18 to 41 years, the HR increased to average at about 1.5 and began to decrease thereafter. At the age of 61 years, the HR was below 1.13, not significant at the age of 74 years and significantly less than 1 at the age of 83 years. This led us to stratify patients in two age ranges: 17--61 years ([Table 3](#pone-0061955-t003){ref-type="table"}) and 62--84 years ([Table 4](#pone-0061955-t004){ref-type="table"}). We applied the same model and again, found that all variables were highly significant at p\<0.00001. The gender effect was more prominent in the age range 17--61 years, with a difference of about 30% in terms of the HR compared with patients over the age of 62 years. To further investigate this phenomenon, Kaplan-Meier analysis was conducted with the same dataset. Differences in survival between females and males were computed at each age and Log-Rank test was used to assess if variation was significant at a p value \<0.05 ([Figure 2](#pone-0061955-g002){ref-type="fig"}, [Video S1](#pone.0061955.s001){ref-type="supplementary-material"}). Until the age of 17 years, no significant changes were noticed. Starting from 18 years of age, an increasing and statistically significant difference was found. This effect peaked around 27 years and slightly decreased thereafter, remaining significant until the age of 63 years. After 70 years, the opposite phenomenon was noticed, with males having a slight but significant survival advantage. In terms of racial groups, the gender effect was more prominent in African-Americans than in Caucasians ([Fig. 3A](#pone-0061955-g003){ref-type="fig"}). In terms of tumor type, the gender effect was equally represented in sarcomas and epithelial solid tumors, but not in hematopoietic malignancies ([Fig. 3B](#pone-0061955-g003){ref-type="fig"}). In terms of staging, the gender effect was maximal in the most aggressive tumors with metastatic disease, slightly displayed in tumors with regional involvement and inverted in patients with localized disease, with males barely outliving females ([Fig. 3C](#pone-0061955-g003){ref-type="fig"}).

![Distribution of HR (female = 1) in the age range 1--84 of patients in the SEER-18 database.\
Each point represents the value of HR measured with the Cox multivariate model. Bars indicate the CI interval. Green, not significant; Red, significant (P\<0.05). The dotted line is the reference while the dashed indicates the HR value obtained without stratification by age (1.126). HR is not significant in the age range 1--17. In the age 18--61 it is constantly higher than 1.126 while after 62 is lower. At age 74 is not longer significant, to become again significant after 83 with a value lower than 1.](pone.0061955.g001){#pone-0061955-g001}

![Difference in 5 years survival calculated with the Kaplan Meier method.\
A positive value means that females have a survival advantage as compared with males. Green, not significant; Red, significant (P\<0.05). In the interval 17--63 males exhibited the worst outcome as compared with females with differences averaging more than 10% until the age of 45.](pone.0061955.g002){#pone-0061955-g002}

![Kaplan-Meier plot according to A: Race. Blue, males; Red, females; Continuous lines, African-American; dashed lines, Caucasian; B: Type of tumor; Blue, males; Red, females; Continuous, epithelial solid tumors; dotted, hematologic malignancies; dashed, sarcomas; C: Tumor stage, Blue, males; Red, females; Continuous, distant; dotted, regional; dashed, localized disease.\
The major by gender differences are evident in conditions where tumors are featured by high mortality.](pone.0061955.g003){#pone-0061955-g003}
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###### Multivariate Cox analysis from the SEER 18 database for patients stratified for age range 17--61.
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                        Number of patients   Number of deaths   HR[\*](#nt102){ref-type="table-fn"}   95% CI\*\*   P-Value
  -------------------- -------------------- ------------------ ------------------------------------- ------------ ---------
  **Age 17**--**61**                                                                                              
  **Gender**                                                                                                       \<2e-16
  Female                     214,647              51,416                   1 (Reference)                          
  Male                       282,084              89,748                       1.31                   1.30--1.33  
  **Age**                                                                      1.03                   1.03--1.03   \<2e-16
  **Race**                                                                                                         \<2e-16
  African-American            61,907              25,479                   1 (Reference)                          
  Caucasian                  434,824             115,685                       0.69                   0.68--0.70  
  **Tumor**                                                                                                        \<2e-16
  Hematological               37,012              11,299                   1 (Reference)                          
  Sarcoma                     12,274              2,765                        1.87                   1.79--1.95  
  Solid                      447,445             127,100                       2.10                   2.05--2.14  
  **Stage**                                                                                                        \<2e-16
  Distant                    149,360              72,675                   1 (Reference)                          
  Localized                  238,439              23,656                       0.14                   0.14--0.15  
  Regional                   108,932              44,833                       0.68                   0.67--0.69  
  **Gender**                                                                                                       \<2e-16

HR = Hazard Ratio \*\*CI = Confidence Interval.

10.1371/journal.pone.0061955.t004

###### Multivariate Cox analysis from the SEER 18 database for patients stratified for age range 62--84.
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                        Number of patients   Number of deaths   HR[\*](#nt103){ref-type="table-fn"}   95% CI\*\*   P-Value
  -------------------- -------------------- ------------------ ------------------------------------- ------------ ---------
  **Gender**                                                                                                       \<2e-16
  **Age 62**--**84**                                                                                              
  Female                     297,522             133,296                   1 (Reference)                          
  Male                       388,217             164,464                       1.04                   1.03--1.04  
  **Age**                                                                      1.03                   1.03--1.03   \<2e-16
  **Race**                                                                                                         \<2e-16
  African-American            64,346              32,807                   1 (Reference)                          
  Caucasian                  621,393             264,953                       0.81                   0.79--0.82  
  **Tumor**                                                                                                        \<2e-16
  Hematological               53,763              23,409                   1 (Reference)                          
  Sarcoma                     6,655               2,279                        1.40                   1.33--1.46  
  Solid                      625,321             272,072                       1.70                   1.68--1.72  
  **Stage**                                                                                                        \<2e-16
  Distant                    259,208             150,582                   1 (Reference)                          
  Localized                  284,555              61,033                       0.26                   0.25--0.26  
  Regional                   141,976              86,145                       0.92                   0.92--0.93  

HR = Hazard Ratio \*\*CI = Confidence Interval.

To identify potential biological causes of the gender effect, we analyzed a series of physiologic variables assessed in the NHANES III study population. All variables were computed across the age range for the available population sample (n = 29,314). Spearman correlation test by gender was made between the distribution of HR and each of the NHANES III variables ([Table 5](#pone-0061955-t005){ref-type="table"}). The strongest correlation was noticed for Free Testosterone Index (FTI) in males with an R value of 0.9 ([Fig. 4](#pone-0061955-g004){ref-type="fig"}).

![Dot Plot showing the correlation (orange line) between FTI (Y-axis) and HR (X-axis).\
Each data point (n = 72) is the median of the values for the range 12--84.](pone.0061955.g004){#pone-0061955-g004}
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###### Homology of the NHANES III parameters with the distribution of HR calculated with the Spearman correlation test.
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  Name[\*](#nt104){ref-type="table-fn"}                    Variable                   R-Female\*\*   P-value Female   R-Male\*\*   P-value Male
  --------------------------------------- ------------------------------------------ -------------- ---------------- ------------ --------------
  AAP                                          Serum apolipoprotein AI (mg/dL)           −0.192        0.08641129       −0.281      0.01092914
  AAPSI                                       Serum apolipoprotein AI: SI (g/L)          −0.192        0.08641129       −0.281      0.01098927
  ABP                                           Serum apolipoprotein B (mg/dL)           −0.271        0.01447273       −0.042      0.71236907
  ABPSI                                        Serum apolipoprotein B: SI (g/L)          −0.271        0.01427207       −0.042      0.71236907
  ACP                                            Serum alpha carotene (ug/dL)            −0.357        0.00106457       −0.269      0.01525548
  ACPSI                                       Serum alpha carotene: SI (umol/L)          −0.357        0.00106457       −0.249      0.02525033
  AMP                                                Serum albumin (g/dL)                0.337         0.00356104       0.749       0.00000000
  AMPSI                                            Serum albumin: SI (g/L)               0.339         0.00339225       0.749       0.00000000
  APPSI                                      Serum alkaline phosphatase: SI (U/L)        −0.813        0.00000000       −0.417      0.00023949
  ASPSI                                      Aspartate aminotransferase: SI(U/L)         −0.798        0.00000000       0.589       0.00000004
  ATPSI                                       Alanine aminotransferase: SI (U/L)         0.099         0.40254662       0.772       0.00000000
  BCP                                            Serum beta carotene (ug/dL)             −0.627        0.00000000       −0.814      0.00000000
  BCPSI                                        Serum beta carotene: SI (umol/L)          −0.627        0.00000000       −0.811      0.00000000
  BUP                                         Serum blood urea nitrogen (mg/dL)          −0.749        0.00000000       −0.735      0.00000000
  BUPSI                                     Serum blood urea nitrogen: SI (mmol/L)       −0.750        0.00000000       −0.735      0.00000000
  BXP                                          Serum beta cryptoxanthin (ug/dL)          −0.575        0.00000002       0.114       0.30923053
  BXPSI                                     Serum beta cryptoxanthin: SI (umol/L)        −0.575        0.00000002       0.114       0.30923053
  C1P                                             Serum C-peptide (pmol/mL)              −0.853        0.00000000       −0.900      0.00000000
  C1PSI                                          Serum C-peptide: SI (nmol/L)            −0.853        0.00000000       −0.900      0.00000000
  C3PSI                                         Serum bicarbonate: SI (mmol/L)           −0.719        0.00000000       −0.146      0.21736862
  CAPSI                                        Serum total calcium: SI (mmol/L)          −0.360        0.00176134       0.649       0.00000000
  CEP                                              Serum creatinine (mg/dL)              −0.735        0.00000000       −0.560      0.00000026
  CEPSI                                         Serum creatinine: SI (umol/L)            −0.735        0.00000000       −0.564      0.00000021
  CHP                                             Serum cholesterol (mg/dL)              −0.632        0.00000000       −0.300      0.00991549
  CHPSI                                         Serum cholesterol: SI (mmol/L)           −0.632        0.00000000       −0.300      0.00991549
  CLPSI                                          Serum chloride: SI (mmol/L)             0.749         0.00000000       0.305       0.00874252
  CRP                                          Serum C-reactive protein (mg/dL)          0.120         0.28496126       −0.526      0.00000045
  DWP                                          Platelet distribution width (%)           −0.209        0.05619882       −0.273      0.01210983
  EPP                                         Erythrocyte protoporphyrin (ug/dL)         0.129         0.24269588       −0.821      0.00000000
  EPPSI                                    Erythrocyte protoporphyrin: SI (umol/L)       0.129         0.24269588       −0.821      0.00000000
  FBP                                             Plasma fibrinogen (mg/dL)              −0.785        0.00000000       −0.875      0.00000000
  FBPSI                                          Plasma fibrinogen: SI (g/L)             −0.785        0.00000000       −0.875      0.00000000
  FEP                                                 Serum iron (ug/dL)                 0.245         0.02495242       0.810       0.00000000
  FEPSI                                            Serum iron: SI (umol/L)               0.245         0.02495242       0.811       0.00000000
  FHPSI                                              Serum FSH: SI (IU/L)                −0.923        0.00000000         NA            NA
  FOP                                                Serum folate (ng/mL)                −0.848        0.00000000       −0.878      0.00000000
  FOPSI                                           Serum folate: SI (nmol/L)              −0.849        0.00000000       −0.878      0.00000000
  FRP                                               Serum ferritin (ng/mL)               −0.309        0.00425086       0.313       0.00377445
  FRPSI                                           Serum ferritin: SI (ug/L)              −0.309        0.00425086       0.313       0.00377445
  FTI                                              Free Testosterone Index                 NA              NA           0.896       0.00000000
  G1P                                               Plasma glucose (mg/dL)               −0.935        0.00000000       −0.893      0.00000000
  G1PSI                                          Plasma glucose: SI (mmol/L)             −0.935        0.00000000       −0.894      0.00000000
  GBP                                               Serum globulin (g/dL)                0.493         0.00000959       −0.508      0.00000442
  GBPSI                                            Serum globulin: SI (g/L)              0.493         0.00000959       −0.508      0.00000442
  GGPSI                                      Gamma glutamyl transferase: SI(U/L)         −0.309        0.00784222       0.300       0.00982023
  GHP                                              Glycated hemoglobin: (%)              −0.458        0.00001750       −0.328      0.00281080
  GRP                                            Granulocyte number (Coulter)            0.330         0.00219745       −0.156      0.15681130
  GRPPCNT                                       Granulocyte percent (Coulter)            0.099         0.36796983       −0.209      0.05677155
  HDP                                           Serum HDL cholesterol (mg/dL)            −0.026        0.81885388       −0.028      0.80150034
  HDPSI                                       Serum HDL cholesterol: SI (mmol/L)         −0.026        0.81647053       −0.033      0.77302280
  HGP                                                 Hemoglobin (g/dL)                  −0.201        0.06652643       0.888       0.00000000
  HGPSI                                              Hemoglobin: SI (g/L)                −0.207        0.05936647       0.887       0.00000000
  HTP                                                   Hematocrit (%)                   −0.230        0.03530110       0.882       0.00000000
  HTPSI                                            Hematocrit: SI (L/L = 1)              −0.261        0.01662213       0.882       0.00000000
  I1P                                               Serum insulin (uU/mL)                −0.388        0.00140917       −0.631      0.00000002
  I1PSI                                           Serum insulin: SI (pmol/L)             −0.397        0.00106616       −0.646      0.00000001
  ICPSI                                     Serum normalized calcium: SI (mmol/L)        −0.181        0.12583385       0.592       0.00000003
  LCP                                           Serum LDL cholesterol (mg/dL)            −0.649        0.00000000       −0.278      0.01716036
  LCPSI                                       Serum LDL cholesterol: SI (mmol/L)         −0.648        0.00000000       −0.279      0.01664851
  LDPSI                                     Serum lactate dehydrogenase: SI (U/L)        −0.872        0.00000000       −0.603      0.00000002
  LHPSI                                      Serum luteinizing hormone: SI (IU/L)        −0.900        0.00000000         NA            NA
  LMP                                            Lymphocyte number (Coulter)             0.112         0.31063595       0.111       0.31586929
  LMPPCNT                                        Lymphocyte percent (Coulter)            −0.031        0.77844359       0.226       0.03867549
  LUP                                          Serum lutein/zeaxanthin (ug/dL)           −0.503        0.00000166       −0.186      0.09706599
  LUPSI                                      Serum lutein/zeaxanthin: SI (umol/L)        −0.503        0.00000166       −0.185      0.09862355
  LYP                                               Serum lycopene (ug/dL)               0.581         0.00000001       0.693       0.00000000
  LYPSI                                          Serum lycopene: SI (umol/L)             0.581         0.00000001       0.696       0.00000000
  MCPSI                                         Mean cell hemoglobin: SI (pg)            −0.098        0.37316009       −0.102      0.35591627
  MHP                                         Mean cell hemoglobin concentration         −0.025        0.81809731       0.713       0.00000000
  MHPSI                                     Mean cell hemoglobin concentration: SI       −0.041        0.71258807       0.712       0.00000000
  MOP                                            Mononuclear number (Coulter)            −0.459        0.00001110       −0.270      0.01296002
  MOPPCNT                                       Mononuclear percent (Coulter)            −0.694        0.00000000       −0.303      0.00502804
  MVPSI                                           Mean cell volume: SI (fL)              −0.162        0.14189878       −0.196      0.07470494
  NAPSI                                           Serum sodium: SI (mmol/L)              −0.730        0.00000000       0.121       0.30861718
  OSPSI                                         Serum osmolality: SI (mmol/Kg)           −0.774        0.00000000       −0.610      0.00000001
  PBP                                                    Lead (ug/dL)                    −0.716        0.00000000       −0.366      0.00061883
  PBPSI                                               Lead: SI (umol/L)                  −0.716        0.00000000       −0.365      0.00063950
  PLP                                                   Platelet count                   0.164         0.13599759       0.170       0.12316988
  PLPSI                                               Platelet count: SI                 0.164         0.13599759       0.170       0.12316988
  PSP                                              Serum phosphorus (mg/dL)              −0.092        0.43837499       0.592       0.00000003
  PSPSI                                         Serum phosphorus: SI (mmol/L)            −0.105        0.37698728       0.601       0.00000002
  PVPSI                                         Mean platelet volume: SI (fL)            0.263         0.01556216       0.509       0.00000076
  PXP                                          Serum transferrin saturation (%)          0.004         0.97279399       0.651       0.00000000
  RBP                                                 RBC folate (ng/mL)                 −0.697        0.00000000       −0.829      0.00000000
  RBPSI                                            RBC folate: SI (nmol/L)               −0.697        0.00000000       −0.830      0.00000000
  RCP                                                Red blood cell count                −0.389        0.00025433       0.894       0.00000000
  RCPSI                                            Red blood cell count: SI              −0.389        0.00025433       0.894       0.00000000
  REP                                          Serum sum retinyl esters (ug/dL)          −0.478        0.00000631       0.197       0.07756829
  REPSI                                     Serum sum retinyl esters: SI (umol/L)        −0.478        0.00000631       0.197       0.07756829
  RWP                                          Red cell distribution width (%)           −0.213        0.05126613       −0.453      0.00001495
  RWPSI                                    Red cell distribution width:SI(fraction)      −0.201        0.06649576       −0.466      0.00000773
  SCP                                            Serum total calcium (mg/dL)             −0.757        0.00000000       0.498       0.00000753
  SCPSI                                        Serum total calcium: SI (mmol/L)          −0.757        0.00000000       0.498       0.00000753
  SEP                                               Serum selenium (ng/mL)               −0.373        0.00115565       0.050       0.67213796
  SEPSI                                          Serum selenium: SI (nmol/L)             −0.373        0.00115565       0.049       0.67829545
  SFP                                                 Serum iron (ug/dL)                 0.111         0.34785293       0.769       0.00000000
  SFPSI                                            Serum iron: SI (umol/L)               0.120         0.31127706       0.769       0.00000000
  SGP                                               Serum glucose (mg/dL)                −0.798        0.00000000       −0.695      0.00000000
  SGPSI                                           Serum glucose: SI (mmol/L)             −0.798        0.00000000       −0.695      0.00000000
  SKPSI                                          Serum potassium: SI (mmol/L)            −0.740        0.00000000       −0.764      0.00000000
  TBP                                           Serum total bilirubin (mg/dL)            −0.160        0.17761841       0.349       0.00245347
  TBPSI                                       Serum total bilirubin: SI (umol/L)         −0.160        0.17761841       0.349       0.00245347
  TCP                                             Serum cholesterol (mg/dL)              −0.309        0.00506787       −0.064      0.56742948
  TCPSI                                         Serum cholesterol: SI (mmol/L)           −0.310        0.00491528       −0.064      0.57120680
  TGP                                            Serum triglycerides (mg/dL)             −0.432        0.00005590       −0.094      0.40159299
  TGPSI                                        Serum triglycerides: SI (mmol/L)          −0.432        0.00005530       −0.093      0.40818301
  TIP                                                 Serum TIBC (ug/dL)                 0.439         0.00002980       0.225       0.03940973
  TIPSI                                            Serum TIBC: SI (umol/L)               0.439         0.00002920       0.225       0.03946738
  TPP                                             Serum total protein (g/dL)             0.540         0.00000081       0.661       0.00000000
  TPPSI                                         Serum total protein: SI (g/L)            0.540         0.00000081       0.661       0.00000000
  TRP                                            Serum triglycerides (mg/dL)             −0.647        0.00000000       −0.356      0.00200854
  TRPSI                                        Serum triglycerides: SI (mmol/L)          −0.648        0.00000000       −0.357      0.00191951
  UAP                                              Serum uric acid (mg/dL)               −0.799        0.00000000       −0.118      0.31931443
  UAPSI                                          Serum uric acid: SI (umol/L)            −0.799        0.00000000       −0.103      0.38586985
  UBP                                              Urinary albumin (ug/mL)               −0.389        0.00040086       −0.529      0.00000054
  UDP                                              Urinary cadmium (ng/mL)               −0.198        0.07995458       −0.264      0.01867397
  UDPSI                                          Urinary cadmium: SI (nmol/L)            −0.197        0.08239987       −0.257      0.02218103
  UIP                                               Urinary iodine (ug/dL)               0.090         0.43194652       −0.127      0.26442096
  URP                                             Urinary creatinine (mg/dL)             0.665         0.00000000       0.832       0.00000000
  URPSI                                        Urinary creatinine: SI (mmol/L)           0.666         0.00000000       0.832       0.00000000
  VAP                                              Serum vitamin A (ug/dL)               −0.316        0.00400679       −0.125      0.26576601
  VAPSI                                          Serum vitamin A: SI (umol/L)            −0.316        0.00402357       −0.125      0.26570892
  VBP                                             Serum vitamin B12 (pg/mL)              −0.246        0.02668772       0.177       0.11346459
  VBPSI                                         Serum vitamin B12: SI (pmol/L)           −0.245        0.02733610       0.177       0.11381964
  VCP                                              Serum vitamin C (mg/dL)               −0.793        0.00000000       −0.357      0.00124030
  VCPSI                                          Serum vitamin C: SI (mmol/L)            −0.794        0.00000000       −0.357      0.00123505
  VEP                                              Serum vitamin E (ug/dL)               −0.390        0.00032274       −0.245      0.02737352
  VEPSI                                          Serum vitamin E: SI (umol/L)            −0.390        0.00032274       −0.245      0.02731578
  WCP                                               White blood cell count               0.041         0.70884419       −0.347      0.00121351
  WCPSI                                           White blood cell count: SI             0.041         0.70884419       −0.347      0.00121351

Name of the variable in the attached dataset file;\*\*calculated with Spearman Correlation test;

The homology between HR and the NHANES III was then computed for all the available variables across the available age range. KS test assessed the hypothesis that HR and a given NHANES III parameter followed in whole or in part the same distribution. This analysis was performed independently for each gender ([Table 6](#pone-0061955-t006){ref-type="table"}). A striking full homology (100%) was observed for FTI in males, as the two distributions did not differ significantly across the entire age range ([Fig. 5A](#pone-0061955-g005){ref-type="fig"}). None of the other variables exhibited a similar degree of concordance with the HR distribution. The second strongest homology was observed for Hemoglobin in males (11.9%, [Fig. 5B](#pone-0061955-g005){ref-type="fig"}), where the homology was mostly confined to the age range 17--27. Noteworthy, the behavior of hemoglobin in females did not show a comparable homology with HR ([Fig. 5B](#pone-0061955-g005){ref-type="fig"}).

![Homology between HR distribution and FTI.\
(A): Double Y chart reporting HR (left Y-axis; red) and FTI (right Y-axis; green) over age in years (X-axis). Homology between HR distribution and Hemoglobin (HGB) (B). Double Y chart reporting HR (left Y-axis; red) and HGB (right Y-axis; green males, blue females) over age in years (X-axis).](pone.0061955.g005){#pone-0061955-g005}
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###### Homology of the NHANES III parameters with the distribution of HR calculated with the KS method.

![](pone.0061955.t006){#pone-0061955-t006-6}

  Number                    Parameter                   \% Homology Female   \% Homology Male
  --------- ------------------------------------------ -------------------- ------------------
  **1**          Serum apolipoprotein AI (mg/dL)               6.2%                2.5%
  **2**         Serum apolipoprotein AI: SI (g/L)              6.2%                2.5%
  **3**           Serum apolipoprotein B (mg/dL)               3.7%                3.7%
  **4**          Serum apolipoprotein B: SI (g/L)              3.7%                3.7%
  **5**            Serum alpha carotene (ug/dL)                1.2%                0.0%
  **6**         Serum alpha carotene: SI (umol/L)              2.5%                0.0%
  **7**                Serum albumin (g/dL)                    0.0%                1.4%
  **8**              Serum albumin: SI (g/L)                   0.0%                1.4%
  **9**        Serum alkaline phosphatase: SI (U/L)            1.4%                0.0%
  **10**       Aspartate aminotransferase: SI(U/L)             1.4%                1.4%
  **11**        Alanine aminotransferase: SI (U/L)             2.7%                1.4%
  **12**           Serum beta carotene (ug/dL)                 2.5%                1.2%
  **13**         Serum beta carotene: SI (umol/L)              2.5%                1.2%
  **14**        Serum blood urea nitrogen (mg/dL)              2.7%                0.0%
  **15**      Serum blood urea nitrogen: SI (mmol/L)           2.7%                0.0%
  **16**         Serum beta cryptoxanthin (ug/dL)              0.0%                0.0%
  **17**      Serum beta cryptoxanthin: SI (umol/L)            0.0%                0.0%
  **18**            Serum C-peptide (pmol/mL)                  0.0%                0.0%
  **19**           Serum C-peptide: SI (nmol/L)                0.0%                0.0%
  **20**          Serum bicarbonate: SI (mmol/L)               0.0%                0.0%
  **21**         Serum total calcium: SI (mmol/L)              0.0%                1.4%
  **22**             Serum creatinine (mg/dL)                  0.0%                0.0%
  **23**          Serum creatinine: SI (umol/L)                0.0%                0.0%
  **24**            Serum cholesterol (mg/dL)                  0.0%                0.0%
  **25**          Serum cholesterol: SI (mmol/L)               0.0%                0.0%
  **26**           Serum chloride: SI (mmol/L)                 1.4%                1.4%
  **27**         Serum C-reactive protein (mg/dL)              3.7%                7.4%
  **28**         Platelet distribution width (%)               2.4%                2.4%
  **29**        Erythrocyte protoporphyrin (ug/dL)             4.8%                1.2%
  **30**     Erythrocyte protoporphyrin: SI (umol/L)           2.4%                1.2%
  **31**            Plasma fibrinogen (mg/dL)                  0.0%                0.0%
  **32**           Plasma fibrinogen: SI (g/L)                 0.0%                0.0%
  **33**                Serum iron (ug/dL)                     1.2%                2.4%
  **34**             Serum iron: SI (umol/L)                   1.2%                2.4%
  **35**               Serum FSH: SI (IU/L)                    0.0%                N.A.
  **36**               Serum folate (ng/mL)                    2.5%                1.2%
  **37**            Serum folate: SI (nmol/L)                  2.5%                1.2%
  **38**              Serum ferritin (ng/mL)                   2.4%                0.0%
  **39**            Serum ferritin: SI (ug/L)                  2.4%                0.0%
  **40**             Free Testosterone Index                   N.A.               100.0%
  **41**              Plasma glucose (mg/dL)                   0.0%                0.0%
  **42**           Plasma glucose: SI (mmol/L)                 0.0%                0.0%
  **43**              Serum globulin (g/dL)                    0.0%                0.0%
  **44**             Serum globulin: SI (g/L)                  0.0%                0.0%
  **45**       Gamma glutamyl transferase: SI(U/L)             0.0%                0.0%
  **46**             Glycated hemoglobin: (%)                  3.7%                6.2%
  **47**           Granulocyte number (Coulter)                1.2%                2.4%
  **48**          Granulocyte percent (Coulter)                3.6%                2.4%
  **49**          Serum HDL cholesterol (mg/dL)                2.5%                1.2%
  **50**        Serum HDL cholesterol: SI (mmol/L)             2.5%                1.2%
  **51**                Hemoglobin (g/dL)                      1.2%               11.9%
  **52**               Hemoglobin: SI (g/L)                    1.2%               10.7%
  **53**                  Hematocrit (%)                       2.4%               10.7%
  **54**             Hematocrit: SI (L/L = 1)                  1.2%               10.7%
  **55**              Serum insulin (uU/mL)                    0.0%                0.0%
  **56**            Serum insulin: SI (pmol/L)                 0.0%                0.0%
  **57**      Serum normalized calcium: SI (mmol/L)            0.0%                1.4%
  **58**          Serum LDL cholesterol (mg/dL)                0.0%                0.0%
  **59**        Serum LDL cholesterol: SI (mmol/L)             0.0%                0.0%
  **60**      Serum lactate dehydrogenase: SI (U/L)            0.0%                0.0%
  **61**       Serum luteinizing hormone: SI (IU/L)            0.0%                N.A.
  **62**           Lymphocyte number (Coulter)                 1.2%                0.0%
  **63**           Lymphocyte percent (Coulter)                1.2%                0.0%
  **64**         Serum lutein/zeaxanthin (ug/dL)               2.5%                3.7%
  **65**       Serum lutein/zeaxanthin: SI (umol/L)            2.5%                3.7%
  **66**              Serum lycopene (ug/dL)                   0.0%                1.2%
  **67**           Serum lycopene: SI (umol/L)                 0.0%                1.2%
  **68**          Mean cell hemoglobin: SI (pg)                2.4%                2.4%
  **69**        Mean cell hemoglobin concentration             0.0%                2.4%
  **70**      Mean cell hemoglobin concentration: SI           1.2%                1.2%
  **71**           Mononuclear number (Coulter)                0.0%                1.2%
  **72**          Mononuclear percent (Coulter)                0.0%                1.2%
  **73**            Mean cell volume: SI (fL)                  6.0%                6.0%
  **74**            Serum sodium: SI (mmol/L)                  1.4%                1.4%
  **75**          Serum osmolality: SI (mmol/Kg)               0.0%                1.4%
  **76**                   Lead (ug/dL)                        3.6%                6.0%
  **77**                Lead: SI (umol/L)                      3.6%                6.0%
  **78**                  Platelet count                       1.2%                0.0%
  **79**                Platelet count: SI                     1.2%                0.0%
  **80**             Serum phosphorus (mg/dL)                  0.0%                1.4%
  **81**          Serum phosphorus: SI (mmol/L)                0.0%                1.4%
  **82**          Mean platelet volume: SI (fL)                1.2%                2.4%
  **83**         Serum transferrin saturation (%)              1.2%                3.6%
  **84**                RBC folate (ng/mL)                     2.5%                0.0%
  **85**             RBC folate: SI (nmol/L)                   2.5%                0.0%
  **86**               Red blood cell count                    0.0%                7.1%
  **87**             Red blood cell count: SI                  0.0%                7.1%
  **88**         Serum sum retinyl esters (ug/dL)              0.0%                0.0%
  **89**      Serum sum retinyl esters: SI (umol/L)            0.0%                0.0%
  **90**         Red cell distribution width (%)               7.1%                4.8%
  **91**     Red cell distribution width:SI(fraction)          6.0%                3.6%
  **92**           Serum total calcium (mg/dL)                 0.0%                0.0%
  **93**         Serum total calcium: SI (mmol/L)              0.0%                0.0%
  **94**              Serum selenium (ng/mL)                   0.0%                1.4%
  **95**           Serum selenium: SI (nmol/L)                 0.0%                1.4%
  **96**                Serum iron (ug/dL)                     0.0%                0.0%
  **97**             Serum iron: SI (umol/L)                   0.0%                0.0%
  **98**              Serum glucose (mg/dL)                    1.4%                2.7%
  **99**            Serum glucose: SI (mmol/L)                 1.4%                2.7%
  **100**          Serum potassium: SI (mmol/L)                0.0%                0.0%
  **101**         Serum total bilirubin (mg/dL)                0.0%                0.0%
  **102**       Serum total bilirubin: SI (umol/L)             0.0%                0.0%
  **103**           Serum cholesterol (mg/dL)                  2.5%                4.9%
  **104**         Serum cholesterol: SI (mmol/L)               2.5%                4.9%
  **105**          Serum triglycerides (mg/dL)                 6.2%                4.9%
  **106**        Serum triglycerides: SI (mmol/L)              6.2%                4.9%
  **107**               Serum TIBC (ug/dL)                     0.0%                0.0%
  **108**            Serum TIBC: SI (umol/L)                   0.0%                0.0%
  **109**           Serum total protein (g/dL)                 0.0%                0.0%
  **110**         Serum total protein: SI (g/L)                0.0%                0.0%
  **111**          Serum triglycerides (mg/dL)                 4.1%                2.7%
  **112**        Serum triglycerides: SI (mmol/L)              4.1%                2.7%
  **113**            Serum uric acid (mg/dL)                   1.4%                1.4%
  **114**          Serum uric acid: SI (umol/L)                1.4%                1.4%
  **115**            Urinary albumin (ug/mL)                   1.3%                0.0%
  **116**            Urinary cadmium (ng/mL)                   2.5%                1.3%
  **117**          Urinary cadmium: SI (nmol/L)                2.5%                1.3%
  **118**             Urinary iodine (ug/dL)                   0.0%                0.0%
  **119**           Urinary creatinine (mg/dL)                 3.8%                5.1%
  **120**        Urinary creatinine: SI (mmol/L)               3.8%                5.1%
  **121**            Serum vitamin A (ug/dL)                   6.2%                4.9%
  **122**          Serum vitamin A: SI (umol/L)                6.2%                4.9%
  **123**           Serum vitamin B12 (pg/mL)                  0.0%                1.2%
  **124**         Serum vitamin B12: SI (pmol/L)               0.0%                1.2%
  **125**            Serum vitamin C (mg/dL)                   0.0%                0.0%
  **126**          Serum vitamin C: SI (mmol/L)                0.0%                0.0%
  **127**            Serum vitamin E (ug/dL)                   1.2%                3.7%
  **128**          Serum vitamin E: SI (umol/L)                1.2%                3.7%
  **129**             White blood cell count                   2.4%                2.4%
  **130**           White blood cell count: SI                 2.4%                2.4%

Discussion {#s4}
==========

In this era of personalized medicine, research is now focused on identifying specific biomarkers to tailor the therapeutic approach to both the disease and the unique genetic makeup of the patient. This concept is rapidly advancing in oncology, where differences in the genetic composition of a single tumor may be exploited to select individual targeted therapies. Until now, the search for personalized therapeutic strategies has not taken the impact of gender into consideration. Our study emphasizes that gender may be responsible for significant differences in cancer outcome prevalently in patients 17--61 years of age. These differences have been underestimated in previous studies that did not consider the significance of age for the gender effect. To our knowledge, this is the first study that systematically investigates the gender effect stratified over age as continuous variable using US population data. The only other study that has investigated the gender effect with reference to age was conducted in Europe and found a 5% gender-based survival difference [@pone.0061955-Micheli1], as compared to the 30% effect reported here. This discrepancy could be explained by the heterogeneous European database, overrepresentation of older patients or the study design in which age ranges were chosen arbitrarily [@pone.0061955-Micheli1]. Our initial hypothesis was that, if present, the gender effect would be influenced by age, since the hormonal differences between males and females are maximal in the fertile years; similarly, we expected the gender effect to decrease in influence following those years. This hypothesis was confirmed by our analysis since the gender effect peaked during the fertile years, when hormonal differences are maximal by gender.

What determines the gender effect? So far, the concept of hormone-dependent disease has been confined to prostate and breast cancer, where anti-hormone strategies are principal modalities of therapy. Our findings suggest that sex hormones, more generally, could be key drivers of a malignancy\'s aggressiveness, particularly when cancer is developed at a young age, and may thus be exploited to increase cancer survival rates.

Another important finding in our study is that out of 65 physiologic variables [@pone.0061955-Sempos1], free testosterone displayed the strongest homology to that of the HR. The gender effect has traditionally been explained to result from differences in estrogen levels in the female population, with focus on a female\'s pre- or post-menopausal status. Our study strongly suggests that also androgens could be involved in driving the gender effect. Indeed, the amount of free testosterone in males is not constant throughout life [@pone.0061955-Rohrmann1]. Rather, levels increase at around 17 years, peak in the mid-twenties and gradually decrease thereafter until returning to pre-puberty levels at the age of 61 years.

In our study, the gender effect was more prominent in African-American than in Caucasian. In the US population, young African-Americans exhibit higher bone density and muscle mass [@pone.0061955-Ellis1], all parameters which have been related to increased androgen levels [@pone.0061955-Zmuda1]. At the same time, there is also an increased risk of prostate cancer in African-Americans which has been correlated with higher levels of androgens [@pone.0061955-Litman1]. For these reasons, African-Americans may benefit more of a therapeutic manipulation of the hormonal levels aimed at increasing the effects of metastatic cancer treatments. In addition to free testosterone, we noticed that also the amount of hemoglobin displayed a significant correlation with the gender effect in males but not in females. Hemoglobin levels are known to depend on free testosterone levels in males [@pone.0061955-Utriainen1], thus strengthening the biological link between HR trend in males and circulating androgen levels.

How are androgens involved in cancer mortality? Here we reported that the gender effect is not visible in all the patients, but only when the disease is solid (epithelial and sarcomas but not hematological malignancies) and at an advanced stage which would require additional treatments. This fact suggests the presence of a relationship between gender effect and response/resistance to treatments used for metastatic cancers. Recently, androgens have been reported to activate a prosurvival pathway in colorectal cancer through the overexpression of class III and V β-tubulin isotypes [@pone.0061955-Mariani1]. Class III β-tubulin is an adaptive survival pathway to a harsh microenvironment featured by hypoxia [@pone.0061955-Raspaglio1] and poor nutrient supply [@pone.0061955-Raspaglio2]. In this context, androgens could activate a survival pathway regardless of exposure to such a microenvironment, making a cancer more aggressive and resistant to anoikis, which occurs in the setting of low oxygen and nutrient supply. This would enable cancer cells to metastasize locally and distantly and escape from cancer treatments. These processes could establish a biological ground to explain an androgen-dependent gender effect.

But, do estrogen levels exert some protective effects for cancer survival? This hypothesis, originated by Adami and coll. in 1990 [@pone.0061955-Adami1], cannot be directly excluded in our study, as the NHANES III dataset did not analyze estrogen levels in its female population. However, other female-specific sex hormones whose expression is directly related to estrogen levels, such as FSH and LH [@pone.0061955-Hale1], were investigated in the NHANES III population. None of these hormones exhibited a direct relationship with the HR distribution with both Spearman and KS-test. Moreover, estrogen production in females peaks at around 12 years of age [@pone.0061955-Chumlea1] and decreases at around 50--51 years of age [@pone.0061955-Faddy1], which is earlier than the pattern of free testosterone in males. Such physiological observations suggest that the curve of estrogen production does not match the HR distribution over age reported here.

The major limitation of our study is that all the results are driven from patient population studies and that SEER database and NHANES III include cancer patients and healthy subjects, respectively. Therefore, our analysis was made from two independent subsets and data did not come from the same patients. However, such risk is partially mitigated by the size of the studied populations and the fact that they were coming across US, thus decreasing the risk to be affected by specific treatments delivered in a single Institution.

Nevertheless, our data emphasize the new hypothesis that androgens, rather than estrogens, could be drivers of the gender effect. An array of antiandrogen therapies has been developed for the management of prostate cancer, including drugs that also decrease tissue production of androgens [@pone.0061955-Mostaghel1]. Our population study supports the need of prospective clinical trials to test whether young male cancer patients (aged less than 61 years) with metastatic disease could benefit from therapeutic modulation of male hormone levels.

Supporting Information {#s5}
======================

###### 

**Survival analysis from age 0 to 84.** The video is generated by Kaplan-Meier analysis from the data presented in the manuscript from the age 1 to 84 and the animation is obtained with the overlapping of the 84 images. For each age, blue and red lines indicate the survival curve for male and females, respectively.
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###### 

Click here for additional data file.
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[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: CF MK SS SH GS. Performed the experiments: SH MK. Analyzed the data: SH MK CF JP. Contributed reagents/materials/analysis tools: MK MM. Wrote the paper: CF.
